問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Rheumatology

Division of Dermatology

Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

更新時間：2024-06-13

黃文男HUANG, WEN-NAN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • yij1219@vghtc.gov.tw

Recruiting Trial

47Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃文男

List

92Cases

2022-01-12 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2023-10-16 - 2027-09-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-06-03 - 2026-03-09

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2023-12-01 - 2026-12-28

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-12-02 - 2030-12-09

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2026-12-31

Phase II

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    amlitelimab

Participate Sites
2Sites

Recruiting2Sites

2022-11-01 - 2028-04-30

Phase II/III

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    Efgartigimod PH20 SC

Participate Sites
3Sites

Recruiting3Sites

2023-06-01 - 2026-06-08

Phase III

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    Dazodalibep

Participate Sites
4Sites

Recruiting4Sites

2024-01-15 - 2031-06-30

Phase III

A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’s syndrome

  • Condition/Disease

    Hughes syndrome

  • Test Drug

    VAY736/ianalumabVAY736/ianalumab

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients

  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

1 4 5 6 7 8 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB